Use of any investigational product within  weeks prior to randomization

Participation in another clinical study with an investigational product during the  days prior to first dose of olaparib and temozolomide

Concurrent enrollment in another clinical study or receipt of an investigational product within the last  weeks (participation in the survival follow-up period of a study is not an exclusion criterion)

Active, known, clinically serious infections within the  days prior to first dose of investigational product

Participation in a clinical study with an investigational product within  weeks prior to the start of the study treatment (i.e. D of cycle )

Agree to use condoms until  days following the last dose of investigational product, or

Participation in another clinical study with an investigational product during the last  days

Subject has received treatment with any investigational immunotherapy within  years prior to study screening or has received treatment with any other investigational product within  days prior to study screening

Subject who has been treated with an investigational product and has not completed the entire follow-up period for that investigational product;

Treatment with any investigational product within  days prior to Screening.

Radiation therapy within  weeks of investigational product.

Any other anti cancer agents (eg, hormonal, biological, investigational) within  times the half life prior to investigational product.

Subjects who have participated in a clinical trial within  days of Screening or are scheduled to receive an investigational product.

Previous investigational product (IP) assignment in the present study

Participation in another clinical study with an investigational product during the last  weeks.

Administration of another investigational medicinal product within  days before the screening period.

Participation in another clinical study with an investigational product during the  weeks prior to therapy initiation

Participation in another clinical study with an investigational product during the last  weeks

Participation in another clinical study with an investigational product during the last  month prior to initiation of therapy

Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational medicinal product (IMP) within ?  x the half-life of the IMP prior to day  cycle  of Minnelide.

Participation in another clinical study with an investigational product during the last  months

Participation in another clinical study with an investigational product during the last  weeks

Participation in another clinical study with an investigational product during the last  month

Participation in another clinical study with an investigational product administered during the last  days.

investigational product AGS-CF and/or,

Participation in another clinical study with an investigational product during the last  weeks

Participation in another clinical study with an investigational product during the last  weeks (prior use of bevacizumab in the upfront setting is allowed)

Patients who are currently participating in any other clinical trial of an investigational product

Participation in another clinical study with an investigational product during the last  weeks

Participation in another clinical study with an investigational product for cancer during the last  months

Participation in another clinical study with an investigational product during the last  months (mo)

Hemoglobin >= . g/dL within first  weeks prior to first dose of investigational product

Patients who are currently participating in any other clinical trial of an investigational product

Participation in another clinical study with an investigational product during the last  weeks

The subject must have no measurable disease at the time of investigational product administration\r\n* The subject must complete all prior surgery requiring general anesthesia at least four () weeks before administration of the investigational product; the subject must complete all surgery requiring local/epidural anesthesia at least seventy-two () hours prior to administration of the investigational product\r\n* The subject must complete all prior systemic chemotherapy therapy, and all adverse events have either returned to baseline or have stabilized at least four () weeks prior to administration of the investigational product\r\n* The subject must complete all prior systemic radiation therapy at least four () weeks prior to administration of the investigational product; the subject must complete all prior focal radiation therapy at least two () weeks prior to the administration of the investigational agent; the subject must not have received a radiopharmaceutical within eight () weeks prior to the administration of the investigational product\r\n* The subject may continue hormonal therapy (i.e. tamoxifen, anastrozole) during the study

The subject has a history of anaphylaxis or other serious adverse reactions relating to administration of any components of the investigational product

Treatment with an investigational product during the last  weeks

Participation in another clinical study with an investigational product during the last  months

Receipt of radiation therapy within  weeks prior to starting investigational product, or limited field of radiation for palliation within  weeks of the first dose of investigational product

Intolerance to the investigational product or its excipients, or any condition that would significantly impair and/or prohibit the patient's participation in the study, as per the Investigator's judgment.

Participation in another clinical study with an investigational product (IP) during the last  weeks before the first day of study treatment

Current or recent treatment with any other investigational medicinal product or device

Use of any investigational product within  weeks prior to randomization

Participation in another clinical study with an investigational product during the last  weeks

Participation in another clinical study with an investigational product during the last  weeks or  half-lives prior to starting on treatment.

Participation in another clinical study with an investigational product during the last  weeks

Use of any investigational product within  days prior to randomization

Treatment with any investigational product during the last  days (or a longer period depending on the defined characteristics of the agents used)

Investigational medicinal product within the last  days prior to screening

Investigational medicinal product within the last  days prior to screening

Treatment with any investigational product within <  half-lives for each individual investigational product OR  days prior to randomization

Patient has an investigational medicinal product within the last  days prior to screening.

Had chemotherapy or radiotherapy within  weeks prior to the first day of Investigational Product (IP) administration.

Participation in a therapeutic investigational study within  weeks prior to enrollment, or anticipated treatment with another investigational product while on study; this refers to non-commercially approved investigational drugs different than those used in this protocol

Participation in another clinical study with an investigational product during the last  days

Participation in another clinical study with receipt of an investigational product during the last  weeks

Concurrent enrollment in another therapeutic clinical study or receipt of an investigational product within the last  weeks (participation in the survival follow-up period of a study is not an exclusion criterion)

Current, or recent (within  days, or  half-lives of investigational product) participation in other clinical trials of investigational agents and/or containing interventional procedures deemed contrary to the objectives and conduct of this trial.

Use of any investigational product or investigational medical device within  days prior to enrollment

Patient who will be receiving another investigational product during the study

The patient has received any investigational therapy ?  days prior to start of Investigational Product. Investigational therapy is defined as any medicinal product that is not approved in the country of treatment for any indication, adult or pediatric.

Concurrent use of any other investigational product

Participation in another clinical study with an investigational product during the last  days

Participation in another clinical study with receipt of an investigational product during the last  weeks

Participation in another clinical study with an investigational product during the previous  weeks

Participation in another clinical study with an investigational product during the last  weeks

Exposure to an investigational product or investigational device in another clinical study within  weeks prior to CD, or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study

Participation in a clinical study with an investigational product within  weeks prior to the start of the study treatment (i.e., D of Cycle )

Understand that the (investigational Product) IP could have a potential teratogenic risk.

Prior treatment with any investigational product within the past  weeks

Treatment with any investigational product within  days prior to signing the ICF.

Subjects receiving any other investigational medicinal product or anti-cancer therapy.

Participant has been exposed to an investigational product (IP) or investigational device in another clinical study within  weeks prior to IP administration, or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study

Received an investigational product within  days of study treatment or planned to receive within  days after vaccine administration

The patient has received any investigational or non-registered medicinal product other than the study medi-cation within  days preceding the first dose of study medication or plans to receive such a drug during the study period.

Participation in another clinical study with an investigational product during the last  days

Other investigational product-concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited

Other medications that might interfere with the evaluation of the investigational product

Other investigational product  concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited

Other medications that might interfere with the evaluation of the investigational product

Subjects must be willing to undergo a cystoscopy on study for investigational product removal.

Subjects who have received radiotherapy to the pelvis and/or sternum within one year of first Investigational Product administration

Less than  days since receipt of any investigational product or device. Investigational use/receipt of a medicinal product or device that has been approved by the country's local regulatory authority for any indication is permitted.

RECIPIENT: Other investigational product  concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited

RECIPIENT: Other medications that might interfere with the evaluation of the investigational product

Participation in a trial of an investigational medicinal product within the previous  days

The use of any investigational agent within  days preceding the first dose of the study vaccine or subsequent participation in another clinical trial at any time during the study period, in which the subject will be exposed to an investigational product

Agree to abstain from breastfeeding during study participation and for at least  days after the last dose of IP. Note that the screening serum pregnancy test can also be used as the test prior to starting IP (Investigational Product) if it is performed within the -hour timeframe.

Known clinically-significant doubling in marrow or perIP (INVESTIGATIONAL PRODUCT) heral blood blast percentage (to ? %) in the -week period leading to the first dose of IP (INVESTIGATIONAL PRODUCT) (Cycle , Day )

Use of any of the following within  days prior to the first dose of IP (INVESTIGATIONAL PRODUCT):

Participation in another clinical study with an investigational product during the last  days

Use of any investigational or non-registered product other than the study vaccine within  days preceding the first dose of study vaccine/placebo, or planned use during the study period. However, the investigational use of a registered product to treat the subject's underlying disease, is allowed.

Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. NOTE: Subjects enrolled in this study may also be eligible for a four-year gynaecological follow-up of the HPV- study, in which no investigational product will be administered. Subjects will be invited to the gynaecological follow-up study if either of the following applies:

Subject has previously received VM, or any other investigational product in the past thirty days

testing on site at the institution (urine or serum HCG) within  hours prior to the start of investigational product administration

Use of any other investigational product or device within  days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments

Agrees not to receive any other investigational product or therapy while participating in this study.

Participation in another clinical study with an investigational product during the last  days

Has received an investigational product within the  days prior to Lymphoseek administration

Patients with the use of any investigational product or device, excluding fluorodopa (F-DOPA) scans, within  days prior to dosing

May have received treatment with an investigational product.

Treatment with any investigational product within  days before the first infusion.